Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have been given an average recommendation of “Buy” by the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage […]